

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

ACADIA PHARMACEUTICALS INC  
Form SC 13G/A  
February 11, 2005

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS  
FILED PURSUANT TO RULES 13d-1(b), (c) AND (d)  
AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2(b)  
(Amendment No. 1)\*

Acadia Pharmaceuticals Inc.

-----  
(Name of Issuer)

COMMON STOCK  
-----

(Title of Class of Securities)

004225108  
-----

(CUSIP Number)

December 31, 2004  
-----

Date of Event which Requires Filing of this Statement

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

-----  
CUSIP No. 004225108  
-----

13G

-----  
Page 2 of 11 Pages  
-----

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

1 NAME OF REPORTING PERSON

Biotechnology Value Fund, L.P.

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a)

(b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH

5 SOLE VOTING POWER

0

6 SHARED VOTING POWER

257,089 shares

7 SOLE DISPOSITIVE POWER

0

8 SHARED DISPOSITIVE POWER

257,089 shares

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

257,089 shares

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1.52%

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

12 TYPE OF REPORTING PERSON (See Instructions)

PN

CUSIP No. 004225108

13G

Page 3 of 11 Pages

1 NAME OF REPORTING PERSON

Biotechnology Value Fund II, L.P.

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a)

(b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5 SOLE VOTING POWER
	0
	6 SHARED VOTING POWER
	163,500 shares

7 SOLE DISPOSITIVE POWER

0

8 SHARED DISPOSITIVE POWER

163,500 shares

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

163,500 shares

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
0.97%

12 TYPE OF REPORTING PERSON (See Instructions)  
PN

CUSIP No. 004225108

13G

Page 4 of 11 Pages

1 NAME OF REPORTING PERSON

BVF Investments, L.L.C.

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a) [X]

(b) [ ]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5 SOLE VOTING POWER

NUMBER OF  
SHARES  
BENEFICIALLY

OWNED BY

EACH  
REPORTING  
PERSON  
WITH

0

6 SHARED VOTING POWER

395,000 shares

7 SOLE DISPOSITIVE POWER

0

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

8 SHARED DISPOSITIVE POWER

395,000 shares

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

395,000 shares

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

[ ]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

2.34%

12 TYPE OF REPORTING PERSON (See Instructions)

OO

CUSIP No. 004225108

13G

Page 5 of 11 Pages

1 NAME OF REPORTING PERSON

Investment 10, LLC

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a) [X]

(b) [ ]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Illinois

5 SOLE VOTING POWER

NUMBER OF

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

SHARES 0  
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  
-----  
6 SHARED VOTING POWER  
43,000 shares  
-----  
7 SOLE DISPOSITIVE POWER  
0  
-----  
8 SHARED DISPOSITIVE POWER  
43,000 shares  
-----

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
43,000 shares  
-----

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ]  
-----

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
0.25%  
-----

12 TYPE OF REPORTING PERSON (See Instructions)  
OO  
-----

-----  
CUSIP No. 004225108 13G Page 6 of 11 Pages  
-----

1 NAME OF REPORTING PERSON  
BVF Partners L.P.  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)  
-----

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)  
(a) [X]  
(b) [ ]

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5 SOLE VOTING POWER  
NUMBER OF  
SHARES 0  
BENEFICIALLY

6 SHARED VOTING POWER  
OWNED BY  
EACH 858,589 shares  
REPORTING  
PERSON  
WITH

7 SOLE DISPOSITIVE POWER  
0

8 SHARED DISPOSITIVE POWER  
858,589 shares

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

858,589 shares

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

[ ]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.09%

12 TYPE OF REPORTING PERSON (See Instructions)

PN

CUSIP No. 004225108

13G

Page 7 of 11 Pages

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

1 NAME OF REPORTING PERSON

BVF Inc.

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a)

(b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5 SOLE VOTING POWER
	0
	6 SHARED VOTING POWER
	858,589 shares

7 SOLE DISPOSITIVE POWER

0

8 SHARED DISPOSITIVE POWER

858,589 shares

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

858,589 shares

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.09%

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

12 TYPE OF REPORTING PERSON (See Instructions)

IA, CO

-----  
CUSIP No. 004225108

13G

-----  
Page 8 of 11 Pages  
-----

Item 1(a). Name of Issuer:

Acadia Pharmaceuticals Inc. ("Acadia")

Item 1(b). Address of Issuer's Principal Executive Offices:

3911 Sorrento Valley Blvd.  
San Diego, CA 92121

Item 2(a). Names of Person Filing

This Amendment to Schedule 13G is being filed on behalf of the following persons (the "Reporting Persons"):

- (i) Biotechnology Value Fund, L.P. ("BVF")
- (ii) Biotechnology Value Fund II, L.P. ("BVF2")
- (iii) BVF Investments, L.L.C. ("Investments")
- (iv) Investment 10, L.L.C. ("ILL10")
- (v) BVF Partners L.P. ("Partners")
- (vi) BVF Inc. ("BVF Inc.")

Item 2(b). Address of Principal Business Office or, if none, Residence:

The principal business office of the Reporting Persons comprising the group filing this Amendment to Schedule 13G is located at 227 West Monroe Street, Suite 4800, Chicago, Illinois, 60606.

Item 2(c). Citizenship or Place of Organization:

BVF: a Delaware limited partnership  
BVF2: a Delaware limited partnership  
Investments: a Delaware limited liability company  
ILL10: an Illinois limited liability company  
Partners: a Delaware limited partnership  
BVF Inc.: a Delaware corporation

-----  
CUSIP No. 004225108

13G

-----  
Page 9 of 11 Pages  
-----

Item 2(d). Title of Class of Securities:

## Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

This Amendment to Schedule 13G is being filed with respect to the common stock, par value \$0.0001 per share (the "Common Stock"), of Acadia. The Reporting Persons' percentage ownership of Common Stock is based on 16,866,979 shares of Common Stock being outstanding.

As of December 31, 2004, (i) BVF beneficially owned 257,089 shares of Common Stock; (ii) BVF2 beneficially owned 163,500 shares of Common Stock; (iii) Investments beneficially owned 395,000 shares of Common Stock; and (iv) ILL10 beneficially owned 43,000 shares of Common Stock. Beneficial ownership by Partners and BVF Inc. includes 858,589 shares of Common Stocks.

Item 2(e). CUSIP Number:

004225108

Item 3. If this Statement is Filed Pursuant to Rule 13d-1(B), or 13d-2(B) or (C) Check Whether the Person Filing is: One of the Following

Not applicable as this Amendment to Schedule 13G is filed pursuant to Rule 13d-1(c).

Item 4. Ownership

The information in items 1 and 5 through 11 on the cover pages (pp. 2 - 7) on this Amendment to Schedule 13G is hereby incorporated by reference.

Item 5. Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities check the following. | |

Item 6. Ownership of More than 5 Percent on Behalf of Another Person

Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest funds of Ziff Asset Management, L.P., the majority member of Investments, in shares of Common Stock described herein and to vote and exercise dispositive power over those securities. Partners and BVF Inc. share voting and dispositive power over the shares of Common Stock beneficially owned by BVF, BVF2, Investments and those owned by ILL10, on whose behalf Partners acts as investment manager and, accordingly, Partners and BVF Inc. have beneficial ownership of all of the shares of Common Stock held by such parties.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Securities Being Reported on By the Parent Holding Company

Not Applicable.

Item 8. Identification and Classification of Members of the Group

Not Applicable.

Item 9. Notice of Dissolution of Group

Not Applicable.

-----  
CUSIP No. 004225108  
-----

13G

-----  
Page 10 of 11 Pages  
-----

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2005

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT
-----
Mark N. Lampert
President

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT
-----
Mark N. Lampert
President

BVF INVESTMENTS, L.L.C.

By: BVF Partners L.P., its manager

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT
-----
Mark N. Lampert
President

INVESTMENT 10, L.L.C.

By: BVF Partners L.P., its attorney-in-fact

By: BVF Inc., its general partner

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form SC 13G/A

By: /s/ MARK N. LAMPERT

-----  
Mark N. Lampert  
President

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

-----  
Mark N. Lampert  
President

BVF INC.

By: /s/ MARK N. LAMPERT

-----  
Mark N. Lampert  
President